Cingulate Q3 net loss $4.0M; cash $9.8M, funds only through Q1 2023; Phase 3 ADHD trial starts Dec 2022

Cingulate Inc.

2023-Q3 EPS reported -$1.16

Q3 2022 net loss $4.0M vs $15.3M in Q3 2021; cash and equivalents $9.8M, expected to fund only through first quarter 2023.
Phase 3 adult dose-optimization study for lead ADHD candidate CTx-1301 to commence December 2022; NDA submission targeted H1 2024.
Executed Master Services Agreement with Societal CDMO to manufacture clinical, registration, and commercial batches of CTx-1301.
Anxiety candidate CTx-2103 triple-release buspirone achieved solubility targets; clinical program design underway.
Phase 1/2 bioavailability study for ADHD candidate CTx-1302 (dextroamphetamine) planned for first half 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cingulate Inc. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 14, 2022, Cingulate Inc. (the “Company”) issued a press release announcing its financial results for the third quarter of 2022 and providing a clinical and business update.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Cingulate Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-031575

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.